Aubrey de Grey of the Longevity Escape Velocity (LEV) Foundation predicts that within 12-15 years, we may see therapies capable of extending human lifespan by a few decades. However, widespread availability of these therapies may take longer to achieve. It may also take decades before we fully understand the effects of these rejuvenation therapies on human lifespan. Despite promising advancements in biotech, unexpected delays are common in this field.
While some anti-aging therapies show potential in clinical trials, there is a lack of widespread adoption and data on their long-term effects. The concept of Longevity Escape Velocity (LEV) plays a key role in the pursuit of extending human lifespan by continuously improving medicines. Aubrey de Grey believes that achieving LEV is possible with medicines that can postpone aging by 20 years, possibly within the next 12-15 years. However, addressing all aspects of aging to significantly delay chronic conditions of old age may take an additional decade.
Exciting developments in anti-aging research, such as THIO, a telomerase-targeting anti-cancer drug, show promise in extending lifespan. The field of longevity research is rapidly evolving, with potential breakthrough therapies on the horizon. While there is optimism for extending human lifespans, unexpected hurdles and delays are to be expected in the journey towards significantly prolonging healthy lifespan.
